SuperworthCardiff Oncology shares outstanding CRDF
Diluted shares outstanding, averaged over each quarter, from 2011.
- Latest quarter, to Jun 30, 2026
- 68.4M
- On a year earlier
- +2.8%
- more shares
Cardiff Oncology had 68.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 2.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 67.4M | +24% |
| FY2024 | 54.2M | +21% |
| FY2023 | 44.7M | +0% |
| FY2022 | 44.5M | +10% |
| FY2021 | 40.6M | +14% |
| FY2020 | 35.6M | +327% |
| FY2019 | 8.3M | +117% |
| FY2018 | 3.8M | +587% |
| FY2017 | 558.1K | +31% |
| FY2016 | 426.6K | +2% |
| FY2015 | 418.8K | +58% |
| FY2014 | 264.9K | +1% |
| FY2013 | 262.5K | +28% |
| FY2012 | 204.6K | +39% |
| FY2011 | 147.7K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 68.4M | +3% | |
| Q1 FY26 | 68.3M | +3% | |
| Q4 FY25 | 67.4M | +24% | |
| Q3 FY25 | 66.9M | +43% | |
| Q2 FY25 | 66.5M | +48% | |
| Q1 FY25 | 66.5M | +49% | |
| Q4 FY24 | 54.2M | +21% | |
| Q3 FY24 | 46.9M | +5% | |
| Q2 FY24 | 44.8M | +0% | |
| Q1 FY24 | 44.7M | +0% | |
| Q4 FY23 | 44.7M | +0% | |
| Q3 FY23 | 44.7M | +3% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Cardiff Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.